Jordyn Sava is an assistant editor for Targeted Oncology.
FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in mCRC
August 2nd 2023Trifluridine/tipiracil plus bevacizumab improved rates of progression-free and overall survival vs trifluridine/tipiracil alone in the SUNLIGHT study. Now, the combination is FDA-approved for patients with metastatic colorectal cancer.
KEYNOTE-756 of Pembrolizumab/Chemotherapy Improves pCR in ER+HER2- Breast Cancer
July 31st 2023KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.
NCCN Guidelines Add Flotufolastat F 18 Injection for Prostate Cancer
July 27th 2023Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.
Analysis Supports Consolidative Stem Cell Transplant for CD30+ PTCL Post A+CHP
July 25th 2023Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.
Mature Data From KEYNOTE-826 Study of Pembrolizumab Addition in Cervical Cancer
July 18th 2023Bradley J. Monk, MD, FACS, FACOG, discusses findings from the phase 3 KEYNOTE-826 trial of the addition of pembrolizumab to chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.